| Drug Name | OFEV (nintedanib) |
|---|---|
| Drug Class |
Anti-fibrotic
|
| Risk minimization type |
Safety communication
|
| Specialty (Theraputic area) |
Respiratory Diseases
|
| Risk |
Increased risk of drug-induced liver injuries associated with the use of nintedanib |
| safety communication |
|